HHS sends interim peptide compounding policy covering BPC-157 to White House
The proposal would let certain pharmacies make restricted peptides without facing FDA enforcement, following a July advisory vote to ease limits on six compounds.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 16 13:32 ETSource: The News International
The wire
- 01Robert F. Kennedy Jr.'s department has submitted an interim policy to the White House that could allow specialist pharmacies to compound currently restricted peptides, including BPC-157, the Associated Press reported.
- 02FDA had restricted BPC-157 and other peptides over contamination, allergic reaction and tumor growth concerns; a reversal would reshape what 503A and 503B pharmacies can offer.
- 03External FDA advisers recommended easing restrictions on six peptides in July over agency scientists' objections; the policy remains under White House review and is not final.
From the source
Read at thenews.com.pkWhat is BPC-157? Trump administration considers easing rules on popular peptide injections
The proposal, now under review, could include BPC-157, a substance promoted for muscle growth and injury recovery
